Mark Your Calendars Now! Next Event Ships: September 14, 2015
|
|
- Willis Stanley
- 6 years ago
- Views:
Transcription
1 Agriculture Drive Madison, WI (800) (608) Shipment Date: June 15, 2015 Questions or comments should be directed to Amanda Weiss at x51 or Important Information: PT Central Updates: Enhancements will continue to be added throughout % of participants are reporting results online at PT-Central. Thank you! General instructions are located online at Event Name now appears on your home page next to result entry. Single SAVE function with results editable until the due date. Data submission report now contains attestation signature. Result form and Report Delivery options: The settings for your facility are noted in the demographic information in the upper right corner of your PT Central home page. Results can be entered online or by fax. Online data entry is encouraged. If the data entry option is set to web, paper result forms will not be sent with your PT sample shipments. The Report Delivery option is set to attachment, notification, or Paper. Paper reports will only be mailed to facilities that are not set up to receive s. Please notify us at or use the Contact Us option on the website if you wish to change your data entry or report settings. Specific Sample Notes: Module Page(s) 5090 Gram Stain (GS) Bacteriology Comprehensive (MCP) Bacteriology Limited (MCL) Throat / Urine Bacteriology (TU) Throat / Urine Bacteriology Limited (TUL) Urine Culture (UC) Enteric Pathogens Culture (NP) Mark Your Calendars Now! Next Event Ships: September 14, 2015 Page 1 of 19
2 Please review your reports carefully before filing with the rest of your PT records. Documentation of all decisions and actions concerning incorrect responses should be maintained with your event reports to satisfy regulatory requirements. After trouble-shooting or corrective actions are completed and documented, all reports should be reviewed, signed/initialed by the appropriate personnel, and filed with your proficiency testing records to document your participation. Event Specific Information: Module 5000 (Bacterial Antigens for meningitis) BA-12 N. meningitidis Group B/ E. coli K1: This sample contained N. meningitidis Group B. Participant responses did not reach the 80% peer consensus requirement and, therefore, results were not scored. Laboratories must perform a written self-evaluation of their response to document participation for their lab surveyor. Peer specific data is included in the table below and can be useful for post event troubleshooting and documentation. BA-10 N. meningitidis Group B/E. coli K1 Participant Results Positive Negative BD Directigen 3 10 Wellcogen 1 2 Total 4 12 According to some kit manufacturers, a heating step may affect the sensitivity for the N. meningitidis Group B/E. coli K1 antigen. It is important for laboratories to reference their package inserts for proper sample handling prior to testing. Module 5220 (Neisseria gonorrhoeae): All samples were not scored due to <10 participants reporting results. All laboratories must perform a self-evaluation to document participation for their lab surveyors. Statistics can be found online in the Reports link of your PT-Central account. For the following modules, all analytes and samples achieved 80% peer consensus, matched targets, and were scored accordingly. Laboratories using methods with peer groups of n<10 were scored by the All Methods group. Module 5060 (Clostridium difficile) Module 5070 (CT/GC Detection) Module 5110 (Group A Strep Antigen) Module 5160 (Group A Strep Antigen/Strep Culture) Module 5170 (Group A Strep Culture) Module 5180 (Group B Strep) Module 5200 (MRSA/VRE) Module 5280 (Vaginal Pathogens) Your PT Evaluation Report displays your method peer group and acceptable responses. Statistics are available online under the Reports link of your PT-Central account. References 1. Versalovic, J. (ed) Manual of Clinical Microbiology. 10 th ed. ASM Press, Washington, D.C. Page 2 of 19
3 Module 5090 (Gram Stain) Gram Stain Organisms & Target Responses Sample Sample Contents Gram Reaction Target Morphology GS-6 Staphylococcus aureus Gram positive Cocci GS-7 Fusobacterium nucleatum Gram negative Rods/bacilli GS-8 Neisseria gonorrhoeae Gram negative Diplococci GS-9 Pseudomonas aeruginosa Gram negative Rods/bacilli GS-10 Streptococcus pneumoniae Gram positive Diplococci Sample Gram Stain Referee and Participant Results Analyte Referee Consensus Response Participant GS-6 Gram reaction 100% Gram positive Gram negative * 1 1 Morphology 100% Cocci GS-7 Gram reaction 100% Gram negative Morphology 100% Rods/bacilli GS-8 Gram reaction 100% Gram negative Morphology 100% Diplococci Cocci 9 13 Coccobacilli * 1 1 GS-9 Gram reaction 100% Gram negative Gram positive * 3 4 Morphology 67% ^ Rods/bacilli Coccobacilli Diplococci 2 3 Cocci 2 3 GS-10 Gram reaction 76% ^ Gram positive Gram negative Morphology 62% ^ Diplococci Cocci Coccobacilli Rods/bacilli 6 9 ^Scoring Note: Referee laboratory responses did not reach the 80% consensus requirement and, therefore, results were not scored. received a 100% non-consensus score, and laboratories must perform a written selfevaluation of their response to document participation for their lab surveyor. Sample GS-10 (S. pneumoniae) Note: Technologists should strive to report an interpretation of what is presented on the Gram stain, rather than simply report what is seen. Several participants reported Gram positive coccobacilli, which if reported on a patient would not indicate to the physician what organism may be present. Conversely, reporting Gram positive diplococci (or cocci in pairs) on a patient specimen, would give an early clue of what the organism may be. Page 3 of 19
4 Modules 5030 and 5040 (Bacteriology Comprehensive and Bacteriology Limited) Sample ID Requested Procedure/Analyte(s) Target Organism/Result MC-10 Group A streptococcus antigen Negative for Group A streptococcus antigen MC-11 Group A streptococcus screen Positive for Group A streptococcus MC-12 Neisseria gonorrhoeae screen Positive for Neisseria gonorrhoeae MC-13 Aerobic blood culture Leuconostoc sp. Gram stain Gram positive cocci MC-14 Urine culture Escherichia coli Gram stain Gram negative rods/bacilli Susceptibility testing Appropriate antimicrobials & susceptibilities MC-15 C. difficile antigen detection Positive for C. difficile antigen C. difficile toxin detection Positive for C. difficile toxin MC-16 MRSA screen Positive for MRSA VRE screen Negative for VRE MC-17 Group B streptococcus screen Positive for Group B streptococcus MC-18 Stool Culture Campylobacter jejuni Please note: Samples MC-15 through MC-18 are not included in module 5040 (Bacteriology Limited). MC-10 (Group A streptococcus antigen detection), MC-11 (Group A streptococcus culture), and MC-12 (Neisseria gonorrhoeae screen): All analytes and samples achieved 80% peer consensus, matched targets, and were scored accordingly. Laboratories using methods with peer groups of n<10 were scored by the All Methods group. MC-13 (Aerobic blood culture): Sample contained Leuconostoc species >100,000 CFU/Loop. Referee consensus: Culture = 19% ^ Gram reaction = N/A Gram morphology = N/A Leuconostoc species 1 < 2 Gram positive cocci 4 6 Growth observed (would refer) 7 11 Growth 1 < 2 No Growth Staphylococcus epidermidis group 2 3 Staphylococcus coagulase negative 1 < 2 Gram Stain Responses Gram positive Gram negative 1 4 Cocci Diplococci 1 4 Page 4 of 19
5 ^Scoring Note: Referee laboratory responses did not reach the 80% consensus requirement and, therefore, results were not scored. received a 100% non-consensus score, and laboratories must perform a written selfevaluation of their response to document participation for their lab surveyor. Many labs (75%) observed No growth for this sample both on conventional agar plates and in blood culture bottles. One participant reported obtaining growth only in a thioglycollate broth. It is unclear why the strain in sample MC-13 failed to grow for most labs. Typically, Leuconostoc species do not require any special media and will grow as small alpha-hemolytic or nonhemolytic colonies on blood agar. Leuconostoc species are Gram positive cocci, typically presenting as pairs or chains. Leuconostoc species are catalase negative, PYR and LAP negative, and resistant to vancomycin. Leuconostoc species have been reported as the causal agents in bacteremia, brain abscesses, peritoneal fluid infections and wounds. MC-14 (Urine culture): Sample contained Escherichia coli >1,000,000 CFU/Loop and Lactobacillus species <10,000 CFU/Loop. Referee consensus: Culture = 100% Gram reaction = 100% Gram morphology = 96% Escherichia coli 85 Gram negative rod/bacilli 1 Gram negative bacteria Growth observed (would refer) 15 Growth 26 Gram Stain Responses Gram negative Rods/bacilli Coccobacilli * 4 4 MC-15 (Clostridium difficile toxin/antigen), MC-16 (MRSA/VRE screen), and MC-17 (Group B streptococcus screen): All analytes and samples achieved 80% consensus, matched targets, and were scored accordingly. Laboratories using methods with peer groups of n<10 were scored by the All Methods group. MC-16 Scoring Note (MRSA screen): This sample contained methicillin resistant Staphylococcus aureus (MRSA) and methicillin sensitive S. aureus (MSSA). The MRSA was detected by 81% of participants. Colonies of MRSA and MSSA may appear as different morphologies on routine media. When PT samples or patient specimens grow multiple morphologies of S. aureus, all colony types should be screened for methicillin resistance. Page 5 of 19
6 MC-18 (Stool for enteric pathogens): Sample contained Campylobacter jejuni >1,000,000 CFU/Loop and Klebsiella pneumoniae >100,000 CFU/Loop. Organism Referee Consensus Participant Responses No. of Aeromonas 100% Not identified in stool 36 Campylobacter 100% Campylobacter jejuni 10 Campylobacter species 26 Positive by Immunoassay 12 Not identified in stool * 2 E. coli O157:H7 100% Not identified in stool 47 Not detected 1 Normal Flora isolated ^ 1 Plesiomonas 100% Not identified in stool 34 Salmonella 100% Not identified in stool 55 Normal Flora isolated ^ 1 Shigella 100% Not identified in stool 55 Normal Flora isolated ^ 1 Vibrio 100% Not identified in stool 27 Yersinia 100% No identified in stool 32 ^ This response was not scored General AST Notes: Antimicrobial Susceptibility Testing (AST) Notes Per the Centers for Medicare & Medicaid Services (CMS) requirements, all reported antimicrobials were scored using the CLSI M100-S25 (January 2015) document. AST scores were reduced, per CLIA regulations, for reporting inappropriate antimicrobials. Certain antimicrobials, interpretations, zone sizes, and/or minimum inhibitory concentration (MIC) values were not scored. There was no deduction from participants scores for these responses; however, a written self-evaluation of your response must be performed to document participation for accrediting agencies. reporting MIC values or zone sizes must give both a correct/appropriate MIC or zone size and a correct interpretation in order to receive a passing result for that antimicrobial. For example, if according to the CLSI M100 document, an MIC of 2 for ciprofloxacin should be interpreted as intermediate, and a participant reported an MIC of 2 and an interpretation of susceptible for ciprofloxacin, that antimicrobial would receive a 0%. If you have an AST result that is marked as unsatisfactory on your Evaluation Report even though your interpretation matches the accepted result, it is most likely due to an incorrect MIC or zone size response. Accepted MIC and zone size responses are not shown on your Evaluation Report. Please refer to your CLSI M100-S25 document for antimicrobial agents and their appropriate MIC values and zone sizes. Any time a laboratory is reporting an antimicrobial agent or interpretation that does not correspond to the current version of the CLSI M100 document because of in-house protocols, it should be documented in the Comments section of your results. Page 6 of 19
7 Sample Specific Notes: MC-14 (E. coli in urine) CLSI and FDA Breakpoint Discrepancies: The FDA breakpoints for aztreonam, cefotetan, ceftriaxone, ertapenem, imipenem, and meropenem have been revised to coincide with the current CLSI breakpoints. Information for many antimicrobials, including current FDA breakpoints, can be found at The manufacturers of automated susceptibility systems such as Microscan, Phoenix, and Vitek are required to follow FDA guidelines when setting MIC breakpoints for their automated systems. Some automated systems may be incapable of producing low enough MIC values to accurately follow the current guidelines. Laboratories using these systems must comment on any measures being taken to update susceptibility testing to the current guidelines. Currently, cefotaxime is the only antimicrobial reported on this sample that has a CLSI-FDA breakpoint discrepancy. Laboratories that reported an MIC value that follows FDA cefotaxime breakpoints were Not Scored if a comment was submitted informing WSLH PT that FDA guidelines were being followed. Antimicrobial Agent CLSI/FDA MIC Breakpoint Discrepancy CLSI M100-S25 MIC Breakpoints (µg/ml) FDA Breakpoints (µg/ml) S I R S I R Cefotaxime Not Scored Antimicrobials: The current version of the CLSI-M100 document now has a susceptible dose dependent (SDD) interpretive category. Cefepime is the only antimicrobial in Table 2A, Enterobacteriaceae that has SDD breakpoints. MIC values in the SDD breakpoint range were not scored. The following antimicrobials were not scored due to less than 10 laboratories reporting results: cefdinir, cefixime, cefotetan, cefuroxime-sodium (parenteral), cephalothin, doripenem, fosfomycin, moxifloxacin, norfloxacin, piperacillin, ticarcillin/clavulanate, and trimethoprim. Inappropriate Antimicrobials: Appropriate antimicrobials for E. coli are listed in Table 2A, Enterobacteriaceae, of the CLSI M100-S25 document. Antimicrobials that are considered inappropriate according to this table received a 0% score. Laboratories reporting inappropriate antimicrobials are encouraged to review their susceptibility protocols and only report clinically relevant agents based on organism and specimen source. Page 7 of 19
8 Modules 5250 and 5260 (Throat/Urine Bacteriology and Throat/Urine Bacteriology Limited) Sample ID Requested Procedure/Analyte(s) Primary Target Organism/Result TU-8 Urine culture Aerococcus urinae TU-9 Urine culture No growth Urine culture Escherichia coli TU-10 Gram stain Gram negative rod/bacilli Susceptibility testing Appropriate antimicrobials & susceptibilities TU-11 Group A streptococcus culture Negative for Group A streptococcus TU-12 Group A streptococcus culture Positive for Group A streptococcus TU-13 Group A streptococcus antigen Negative for Group A streptococcus antigen TU-14 Group A streptococcus antigen Negative for Group A streptococcus antigen Please note: Samples TU-13 and TU-14 are not included in the Throat/Urine Bacteriology--Limited (5260) module. TU-8 (Urine culture): Sample contained Aerococcus urinae >1,000,000 CFU/Loop. Referee consensus = 83% Aerococcus species 1 Gram positive cocci 2 Gram positive bacteria 3 56 Growth observed (would refer) 9 Growth 13 No growth * Sample Note: A. urinae has been implicated as a urinary tract pathogen in patients predisposed to infection. The organism forms small alpha-hemolytic, grey colonies on blood agar media. A. urinae is catalase negative and typically presents as clusters on a wet mount or Gram stain. TU-9 (Urine culture): Sample contained no organisms. Referee consensus = 91% No growth Growth observed (would refer) * 1 12 Growth * 5 Page 8 of 19
9 TU-10 (Urine culture): Sample contained Escherichia coli >1,000,000 CFU/Loop and Lactobacillus species <10,000 CFU/Loop. Referee consensus: Culture = 100% Gram reaction = 100% Gram morphology = 96% Escherichia coli 85 Gram negative rod/bacilli 1 Gram negative bacteria Growth observed (would refer) 15 Growth 26 Gram Stain Responses Gram negative Rods/bacilli Coccobacilli * 4 4 TU-11 and TU-12 (Group A streptococcus culture) and TU-13 and TU-14 (Group A streptococcus antigen detection): All samples and analytes achieved 80% peer consensus, matched targets, and were scored accordingly. Laboratories using methods with peer groups of n<10 were scored by the All Methods group. General AST Notes: Antimicrobial Susceptibility Testing (AST) Notes Per the Centers for Medicare & Medicaid Services (CMS) requirements, all reported antimicrobials were scored using the CLSI M100-S25 (January 2015) document. AST scores were reduced, per CLIA regulations, for reporting inappropriate antimicrobials. Certain antimicrobials, interpretations, zone sizes, and/or minimum inhibitory concentration (MIC) values were not scored. There was no deduction from participants scores for these responses; however, a written self-evaluation of your response must be performed to document participation for accrediting agencies. reporting MIC values or zone sizes must give both a correct/appropriate MIC or zone size and a correct interpretation in order to receive a passing result for that antimicrobial. For example, if according to the CLSI M100 document, an MIC of 2 for ciprofloxacin should be interpreted as intermediate, and a participant reported an MIC of 2 and an interpretation of susceptible for ciprofloxacin, that antimicrobial would receive a 0%. If you have an AST result that is marked as unsatisfactory on your Evaluation Report even though your interpretation matches the accepted result, it is most likely due to an incorrect MIC or zone size response. Accepted MIC and zone size Page 9 of 19
10 responses are not shown on your Evaluation Report. Please refer to your CLSI M100-S25 document for antimicrobial agents and their appropriate MIC values and zone sizes. Any time a laboratory is reporting an antimicrobial agent or interpretation that does not correspond to the current version of the CLSI M100 document because of in-house protocols, it should be documented in the Comments section of your results. Sample Specific Notes: TU-10 (E. coli in urine) CLSI and FDA Breakpoint Discrepancies: The FDA breakpoints for aztreonam, cefotetan, ceftriaxone, ertapenem, imipenem, and meropenem have been revised to coincide with the current CLSI breakpoints. Information for many antimicrobials, including current FDA breakpoints, can be found at The manufacturers of automated susceptibility systems such as Microscan, Phoenix, and Vitek are required to follow FDA guidelines when setting MIC breakpoints for their automated systems. Some automated systems may be incapable of producing low enough MIC values to accurately follow the current guidelines. Laboratories using these systems must comment on any measures being taken to update susceptibility testing to the current guidelines. Currently, cefotaxime is the only antimicrobial reported on this sample that has a CLSI-FDA breakpoint discrepancy. Laboratories that reported an MIC value that follows FDA cefotaxime breakpoints were Not Scored if a comment was submitted informing WSLH PT that FDA guidelines were being followed. Antimicrobial Agent CLSI/FDA MIC Breakpoint Discrepancy CLSI M100-S25 MIC Breakpoints (µg/ml) FDA Breakpoints (µg/ml) S I R S I R Cefotaxime Not Scored Antimicrobials: The current version of the CLSI-M100 document now has a susceptible dose dependent (SDD) interpretive category. Cefepime is the only antimicrobial in Table 2A, Enterobacteriaceae that has SDD breakpoints. MIC values in the SDD breakpoint range were not scored. The following antimicrobials were not scored due to less than 10 laboratories reporting results: cefdinir, cefixime, cefotetan, cefuroxime-sodium (parenteral), cephalothin, doripenem, fosfomycin, moxifloxacin, norfloxacin, piperacillin, ticarcillin/clavulanate, and trimethoprim. Inappropriate Antimicrobials: Appropriate antimicrobials for E. coli are listed in Table 2A, Enterobacteriaceae, of the CLSI M100-S25 document. Antimicrobials that are considered inappropriate according to this table received a 0% score. Laboratories reporting inappropriate antimicrobials are encouraged to review their susceptibility protocols and only report clinically relevant agents based on organism and specimen source. Page 10 of 19
11 Sample ID Requested Procedure/Analyte(s) Module 5270 (Urine culture) Target Organism/Result UC-6 Urine culture Klebsiella pneumoniae Gram stain Gram negative rods/bacilli UC-7 Urine culture Aerococcus urinae Gram stain Gram positive cocci UC-8 Urine culture No growth UC-9 Urine culture Candida albicans Gram stain Gram positive yeast Urine culture Escherichia coli UC-10 Gram stain Gram negative rods/bacilli Susceptibility testing Appropriate antimicrobials & susceptibilities Scoring Note: The Gram stain portion of samples UC-6, UC-7 and UC-9 was Not Scored since less than 10 participant laboratories performed this testing. All participants received a 100% score for the Gram stain portion of these samples and must perform a written self-evaluation of their responses to document participation for their lab surveyor. Gram Stain Note: Please note that the Gram stain portion of these samples is meant to demonstrate a laboratory s ability to perform and read Gram stains. Even if a Gram stain was not required to identify a certain organism in a urine culture challenge, it is to the laboratory s advantage to use these samples to show proficiency in Gram staining if it is a procedure being performed in the facility. Please contact the coordinator at x51 with any questions. UC-6: Sample contained Klebsiella pneumoniae >100,000 CFU/Loop and Lactobacillus sp. <10,000 CFU/Loop. Peer consensus (Culture) = 93% Scoring Note: Less than 10 referee laboratories submitted results for this sample; therefore, it was scored by peer consensus. Klebsiella pneumoniae 4 Klebsiella species 1 Growth observed (would refer) 3 93 Growth 6 Enterobacter species * 1 7 Gram Stain Responses (Not Scored) Gram negative 4 80 Gram positive 1 20 Rods/bacilli Page 11 of 19
12 UC-7: Sample contained Aerococcus urinae >1,000,000 CFU/Loop. Referee consensus = 83% Aerococcus species 1 Gram positive cocci 2 Gram positive bacteria 3 56 Growth observed (would refer) 9 Growth 13 No growth * Gram Stain Responses (Not Scored) Gram positive 3 75 Gram negative 1 25 Cocci Sample Note: A. urinae has been implicated as a urinary tract pathogen in patients predisposed to infection. The organism forms small alpha-hemolytic, grey colonies on blood agar media. A. urinae is catalase negative and typically presents as clusters on a wet mount or Gram stain. UC-8: Sample contained no organisms. Referee consensus = 91% No growth Growth observed (would refer) * 1 12 Growth * 5 Page 12 of 19
13 UC-9: Sample contained Candida albicans >100,000 CFU/Loop and Corynebacterium species <10,000 CFU/Loop. Peer consensus (Culture) = 80% Scoring Note: Less than 10 referee laboratories submitted results for this sample; therefore, it was scored by peer consensus. Candida albicans 1 Yeast present 2 Growth observed (would refer) 4 80 Growth 5 Staphylococcus coagulase negative * 1 7 Pseudomonas species * 1 7 No growth * 1 7 Gram Stain Responses (Not Scored) Gram positive Yeast 3 75 Cocci 1 25 UC-10: Sample contained Escherichia coli >1,000,000 CFU/Loop and Lactobacillus species <10,000 CFU/Loop. Referee consensus: Culture = 100% Gram reaction = 100% Gram morphology = 96% Escherichia coli 85 Gram negative rod/bacilli 1 Gram negative bacteria Growth observed (would refer) 15 Growth 26 Gram Stain Responses Gram negative Rods/bacilli Coccobacilli * 4 4 Page 13 of 19
14 Antimicrobial Susceptibility Testing (AST) Notes General AST Notes: Per the Centers for Medicare & Medicaid Services (CMS) requirements, all reported antimicrobials were scored using the CLSI M100-S25 (January 2015) document. AST scores were reduced, per CLIA regulations, for reporting inappropriate antimicrobials. Certain antimicrobials, interpretations, zone sizes, and/or minimum inhibitory concentration (MIC) values were not scored. There was no deduction from participants scores for these responses; however, a written self-evaluation of your response must be performed to document participation for accrediting agencies. reporting MIC values or zone sizes must give both a correct/appropriate MIC or zone size and a correct interpretation in order to receive a passing result for that antimicrobial. For example, if according to the CLSI M100 document, an MIC of 2 for ciprofloxacin should be interpreted as intermediate, and a participant reported an MIC of 2 and an interpretation of susceptible for ciprofloxacin, that antimicrobial would receive a 0%. If you have an AST result that is marked as unsatisfactory on your Evaluation Report even though your interpretation matches the accepted result, it is most likely due to an incorrect MIC or zone size response. Accepted MIC and zone size responses are not shown on your Evaluation Report. Please refer to your CLSI M100-S25 document for antimicrobial agents and their appropriate MIC values and zone sizes. Any time a laboratory is reporting an antimicrobial agent or interpretation that does not correspond to the current version of the CLSI M100 document because of in-house protocols, it should be documented in the Comments section of your results. Sample Specific Notes: UC-10 (E. coli in urine) CLSI and FDA Breakpoint Discrepancies: The FDA breakpoints for aztreonam, cefotetan, ceftriaxone, ertapenem, imipenem, and meropenem have been revised to coincide with the current CLSI breakpoints. Information for many antimicrobials, including current FDA breakpoints, can be found at The manufacturers of automated susceptibility systems such as Microscan, Phoenix, and Vitek are required to follow FDA guidelines when setting MIC breakpoints for their automated systems. Some automated systems may be incapable of producing low enough MIC values to accurately follow the current guidelines. Laboratories using these systems must comment on any measures being taken to update susceptibility testing to the current guidelines. Currently, cefotaxime is the only antimicrobial reported on this sample that has a CLSI-FDA breakpoint discrepancy. Laboratories that reported an MIC value that follows FDA cefotaxime breakpoints were Not Scored if a comment was submitted informing WSLH PT that FDA guidelines were being followed. Antimicrobial Agent CLSI/FDA MIC Breakpoint Discrepancy CLSI M100-S25 MIC Breakpoints (µg/ml) FDA Breakpoints (µg/ml) S I R S I R Cefotaxime Page 14 of 19
15 Not Scored Antimicrobials: The current version of the CLSI-M100 document now has a susceptible dose dependent (SDD) interpretive category. Cefepime is the only antimicrobial in Table 2A, Enterobacteriaceae that has SDD breakpoints. MIC values in the SDD breakpoint range were not scored. The following antimicrobials were not scored due to less than 10 laboratories reporting results: cefdinir, cefixime, cefotetan, cefuroxime-sodium (parenteral), cephalothin, doripenem, fosfomycin, moxifloxacin, norfloxacin, piperacillin, ticarcillin/clavulanate, and trimethoprim. Inappropriate Antimicrobials: Appropriate antimicrobials for E. coli are listed in Table 2A, Enterobacteriaceae, of the CLSI M100-S25 document. Antimicrobials that are considered inappropriate according to this table received a 0% score. Laboratories reporting inappropriate antimicrobials are encouraged to review their susceptibility protocols and only report clinically relevant agents based on organism and specimen source. Page 15 of 19
16 Module 5080 (Enteric Pathogens) Sample ID NP-6 NP-7 NP-8 NP-9 NP-10 Target Organism/Result Shigella flexneri Salmonella Javiana Campylobacter jejuni Escherichia coli O157:H7 Plesiomonas shigelloides NP-6: Sample contained Shigella flexneri >100,000 CFU/Loop, Citrobacter freundii >100,000 CFU/Loop and Escherichia coli >10,000 CFU/Loop. Organism Referee Consensus Participant Responses No. of Aeromonas 100% Not identified in stool 31 Campylobacter 100% Not identified in stool 31 Negative by Immunoassay 7 E. coli O157:H7 100% Not identified in stool 39 Not detected 1 Plesiomonas 100% Not identified in stool 31 Not detected 1 Salmonella 100% Not identified in stool 41 Shigella 100% Shigella flexneri 30 Shigella species 12 Detected 3 Vibrio 100% Not identified in stool 34 Yersinia 100% Not identified in stool 36 Page 16 of 19
17 NP-7: Sample contained Salmonella enterica subspecies enterica serotype Javiana >100,000 CFU/Loop, and Proteus mirabilis >100,000 CFU/Loop. Organism Referee Consensus Participant Responses No. of Aeromonas 100% Not identified in stool 31 Campylobacter 100% Not identified in stool 31 Negative by Immunoassay 7 E. coli O157:H7 100% Not identified in stool 39 Not detected 1 Plesiomonas 100% Not identified in stool 31 Not detected 1 Salmonella 100% Salmonella Javiana 18 Salmonella species 24 Detected 3 Shigella 100% Not identified in stool 42 Vibrio 100% Not identified in stool 34 Yersinia 100% Not identified in stool 36 NP-8: Sample contained Campylobacter jejuni >1,000,000 CFU/Loop and Klebsiella pneumoniae >100,000 CFU/Loop. Organism Referee Consensus Participant Responses No. of Aeromonas 100% Not identified in stool 31 Campylobacter 100% Campylobacter jejuni 21 Campylobacter species 10 Positive by Immunoassay 6 Detected 3 E. coli O157:H7 100% Not identified in stool 39 Not detected 1 Plesiomonas 100% Not identified in stool 31 Not detected 1 Salmonella 100% Not identified in stool 41 Shigella 100% Not identified in stool 42 Vibrio 100% Not identified in stool 34 Yersinia 100% Not identified in stool 36 Page 17 of 19
18 NP-9: Sample contained Escherichia coli O157:H7 >100,000 CFU/Loop and Escherichia coli (non-o157:h7) >100,000 CFU/Loop. Organism Referee Consensus Participant Responses No. of Aeromonas 100% Not Identified in stool 31 Campylobacter 100% Not identified in stool 31 Negative by Immunoassay 7 E. coli O157:H7 100% Escherichia coli O157:H7 20 E. coli O157 - would refer for H7 17 E. coli sorbitol-negative (would refer) 2 Not detected * 1 Plesiomonas 100% Not identified in stool 31 Not detected 1 Salmonella 100% Not identified in stool 41 Shigella 100% Not identified in stool 42 Vibrio 100% Not identified in stool 34 Yersinia 100% Not identified in stool 36 * Incorrect result Page 18 of 19
19 NP-10: Sample contained Plesiomonas shigelloides >10,000 CFU/Loop and Enterobacter aerogenes >10,000 CFU/Loop. Organism Referee Consensus Participant Responses No. of Aeromonas 100% Not identified in stool 31 Campylobacter 100% Not identified in stool 31 Negative by Immunoassay 7 E. coli O157:H7 100% Not identified in stool 39 Not detected 1 Plesiomonas 67% ^ Plesiomonas shigelloides 17 Detected 1 Not identified in stool 14 Salmonella 100% Not identified in stool 41 Shigella 100% Not identified in stool 42 Vibrio 100% Not identified in stool 34 Yersinia 100% Not identified in stool 36 ^Scoring Note: Referee laboratory responses did not reach the 80% consensus requirement; therefore, results were not scored. All responses for Plesiomonas received a 100% non-consensus score, and laboratories must perform a written self-evaluation of their response to document participation for their lab surveyor. Sample Note: This sample contained equal concentrations of P. shigelloides and E. aerogenes, which may have similar morphologies on blood agar. These two organisms can be distinguished by performing an oxidase test (P. shigelloides is oxidase positive). A stool culture can be screened for the presence of Aeromonas, Plesiomonas, and Vibrio species by performing a sweep oxidase test on any blood agar growth. Page 19 of 19
BactiReg3 Event Notes Module Page(s) 4-9 (TUL) Page 1 of 21
www.wslhpt.org 2601 Agriculture Drive Madison, WI 53718 (800) 462-5261 (608) 265-1111 2015-BactiR Reg3 Shipment Date: September 14, 2015 Questions or comments should be directed to Amanda Weiss at 800-462-5261
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationEducating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
More informationmicrobiology testing services
microbiology testing services You already know Spectra Laboratories for a wide array of dialysis-related testing services. Now get to know us for your microbiology needs. As the leading provider of renal-specific
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationINFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationQUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)
Pseudomonas aeruginosa (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Description: Greenish gray colonies with some beta-hemolysis around each colony on blood agar (BAP),
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationPolicy # MI_ENT Department of Microbiology. Page Quality Manual TABLE OF CONTENTS
Quality Manual Version: 2.0 CURRENT 1 of 15 Prepared by QA Committee Issued by: Laboratory Manager Revision Date: 1/2/2018 Approved by Laboratory Director: Annual Review Date: 5/1/2018 Microbiologist-in-Chief
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationGuidelines for Laboratory Verification of Performance of the FilmArray BCID System
Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes quality standards for all laboratory
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More information1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection
Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationAntimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationEUCAST Workshop: Antimicrobial susceptibility testing with EUCAST breakpoints and methods
EUCAST Workshop: Antimicrobial susceptibility testing with EUCAST breakpoints and methods Susceptibility testing of infrequently isolated fastidious organisms Luis Martinez-Martínez Service of Microbiology
More informationBACTERIOLOGY PROFICIENCY TESTING PROGRAM
BACTERIOLOGY PROFICIENCY TESTING PROGRAM Comprehensive Category January 20, 2015 If you have any questions or comments, please contact either: Dr. Wendy Archinal Dr. Kimberlee Musser Phone: (518) 474-4177
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationBacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India
ISSN: 2319-7706 Volume 4 Number 11 (2015) pp. 731-736 http://www.ijcmas.com Original Research Article Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationAdvanced Practice Education Associates. Antibiotics
Advanced Practice Education Associates Antibiotics Overview Difference between Gram Positive(+), Gram Negative(-) organisms Beta lactam ring, allergies Antimicrobial Spectra of Antibiotic Classes 78 Copyright
More informationAntimicrobial susceptibility testing challenges. Linda Joyce St Vincent s Hospital Melbourne
Antimicrobial susceptibility testing challenges Linda Joyce St Vincent s Hospital Melbourne Bacteria/antimicrobials without breakpoints (B.A.W.B.S.) Enterobacteriacae Pseudomonas aeruginosa, Acinetobacter
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationStreptococcus pneumoniae. Oxacillin 1 µg as screen for beta-lactam resistance
Streptococcus pneumoniae Oxacillin µg as screen for beta-lactam resistance Version 6. June Streptococcus pneumoniae and zone diameter correlates The following histograms present inhibition zone diameter
More informationConnections
Winter 2017-2018 ISSN Connections 1496-3876 www.cmpt.ca CMPT Quarterly on -line newsletter Volume 21 Number 4 IN THIS ISSUE What is new at CMPT for 2018?..1 Optimizing microbiology value in small resource
More informationCipro for gram positive cocci in urine
Buscar... Cipro for gram positive cocci in urine 20-6-2017 Pneumonia can be generally defined as an infection of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More informationGram-positive cocci Staphylococci and Streptococcia
Medical microbiology Laboratory Lab 8 Gram-positive cocci Staphylococci and Streptococcia Lecturer Maysam A Mezher Gram positive cocci 1-Staphylococcus. 2-Streptococcus. 3-Micrococcus The medically important
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More informationAntimicrobial Resistance Trends in the Province of British Columbia
655 West 12th Avenue Vancouver, BC V5Z 4R4 Tel 604.707.2443 Fax 604.707.2441 www.bccdc.ca Antimicrobial Resistance Trends in the Province of British Columbia 2013 Prepared by the Do Bugs Need Drugs? Program
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationC&W Three-Year Cumulative Antibiogram January 2013 December 2015
C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...
More information2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital
2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....
More informationتقارير الدروس العملية
وزارة التعليم جامعة الباحة كلية العلوم الطبية التطبيقية قسم طب المختبرات تقارير الدروس العملية مقرر أحياء دقيقة إكلينيكية الدكتور : شائع بن صالح المالكي 5341 ه -5341 ه Routine of Laboratory Diagnosis of
More information2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
More informationMethod Preferences and Test Accuracy of Antimicrobial Susceptibility Testing
Method Preferences and Test Accuracy of Antimicrobial Susceptibility Testing Updates From the College of American Pathologists Microbiology Surveys Program (2000) Ronald N. Jones, MD; for the College of
More informationAvailable online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
More informationSYMMETRY FOAMING HAND SANITIZER with Aloe & Vitamin E Technical Data
508 SYMMETRY FOAMING HAND SANITIZER with Aloe & Vitamin E Technical Data Physical Properties Active Ingredient: Ethyl Alcohol 62% (70% v/v) Appearance: Clear, Colorless Solution Fragrance: Floral Form:
More informationService Delivery and Safety Department World Health Organization, Headquarters
Service Delivery and Safety Department World Health Organization, Headquarters WHO global (laboratory-based) survey on multidrug-resistant organisms (MDROs) in health care PROJECT SUMMARY Given the important
More informationVPM 201-Lab 6 Bovine Mastitis, Bacillus & Mastitis (2012)
Exercise 1. Bovine mastitic milk sample A. Note relevant images are on next page Sample A is Staphylococcus aureus Moderate size (1.0 mm), circular, convex, cream-to-light yellow, opaque Double-zone (target)
More informationRCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
More informationThe Nuts and Bolts of Antibiograms in Long-Term Care Facilities
The Nuts and Bolts of Antibiograms in Long-Term Care Facilities J. Kristie Johnson, Ph.D., D(ABMM) Professor, Department of Pathology University of Maryland School of Medicine Director, Microbiology Laboratories
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More information9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
More informationPerformance Information. Vet use only
Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationInfection Linelist. Infections Occurred Between 10/1/ :00:00 AM To 11/1/ :00:00 AM 2RCW2. Gastroenteritis (Adult) Urinary Tract
Infection Linelist Infections Occurred Between 10/1/2013 12:00:00 AM To 11/1/2013 12:00:00 AM 2RCW2 10/9/13 02407693 36890294 2094 1 32 M CLOSTRIDIUM DIFFICILE 10/26/13 99342791 37024716 2046 1 42 M CLOSTRIDIUM
More informationVitek QC Sets. Vitek 2 Identification QC Sets
Vitek 2 Identification QC Sets MicroBioLogics is selling two types of Vitek 2 microorganism identification sets. They are listed below in two columns. The first column lists the 2008 quality control microorganisms
More information1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
More informationIsolation of Urinary Tract Pathogens and Study of their Drug Susceptibility Patterns
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 4 (2016) pp. 897-903 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.504.101
More informationUNDERSTANDING YOUR DATA: THE ANTIBIOGRAM
UNDERSTANDING YOUR DATA: THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Evansville, IN April.Abbott@Deaconess.com Special thanks to Dr. Shelley Miller for UCLA data WHAT WE WILL COVER
More informationCUMULATIVE ANTIBIOGRAM
BC Children s Hospital and BC Women s Hospital & Health Centre CUMULATIVE ANTIBIOGRAM 2017 Division of Medical Microbiology Department of Pathology and Laboratory Medicine Page 1 of 5 GRAM-POSITIVE BACTERIA
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXVII NUMBER 6 July 2012 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine B. Dowell SM, MLS (ASCP); Sarah K. Parker, MD; James K. Todd, MD Each year the Children s Hospital Colorado
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationUNDERSTANDING THE ANTIBIOGRAM
UNDERSTANDING THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Indiana University School of Medicine - Evansville Evansville, IN April.Abbott@Deaconess.com WHAT WE WILL COVER Describe
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
METHODS USED IN NEW ZEALAND DIAGNOSTIC LABORATORIES TO IDENTIFY AND REPORT EXTENDED-SPECTRUM β-lactamase- PRODUCING ENTEROBACTERIACEAE by Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
More informationM45: INFREQUENTLY ISOLATED OR FASTIDIOUS BACTERIA
M45: INFREQUENTLY ISOLATED OR FASTIDIOUS BACTERIA Romney Humphries, PhD D(ABMM) UCLA Clinical Microbiology Under Revision! ORGANISMS INCLUDED IN M45 VS. M100 M100 Enterobacteriaceae Pseudomonas aeruginosa
More information4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases
4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome
More informationCanadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS
Canadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS FINAL November 29, 2017 Working Group: Joanne Langley (Chair),
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More information5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)
Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health
More informationMedical bacteriology Lecture 8. Streptococcal Diseases
Medical bacteriology Lecture 8 Streptococcal Diseases Streptococcus agalactiae Beat haemolytic Lancifield group B Regularly resides in human vagina, pharynx and large inine Can be transferred to infant
More informationnumber Done by Corrected by Doctor
number 28 Done by Dina Yaseen Corrected by حسام أبو عوض Doctor مالك الزحلف Cephalosporins -Cephalosporins are β-lactam antibiotics isolated from a strain of Streptomyces. -They are bactericidal and work
More informationBacteriology. Mycology. Genova Diagnostics Europe Parkgate House 356 West Barnes Lane New Malden, Surrey. KT3 6NB. Order Number:
Genova Diagnostics Europe Parkgate House 356 West Barnes Lane New Malden, urrey. KT3 6NB Bacteriology Lactobacillus species 3+ Escherichia coli 4+ Bifidobacterium 3+ gamma haemolytic treptococcus NP 4+
More informationRecommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data
Recommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data Trevor Van Schooneveld MD, Scott Bergman, PharmD, BCPS, Paul Fey, PhD, Mark Rupp, MD The Clinical Microbiology laboratory
More informationWhat bugs are keeping YOU up at night?
What bugs are keeping YOU up at night? Barbara DeBaun, RN, MSN, CIC 26 th Annual Medical Surgical Nursing Conference South San Francisco, CA April 15, 2016 Objectives Describe the top three infectious
More informationRecommendations on Surveillance of Antimicrobial Resistance in Ireland
Recommendations on Surveillance of Antimicrobial Resistance in Ireland Background This discussion document was prepared by the Antimicrobial Resistance (AMR) Surveillance Working Group, one of a number
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More information